Compositions and methods of treatment using modulators of motoneuron diseases
The invention disclosed herein describes a novel therapeutic target for motoneuron diseases (altered dynamics of microtubules in neurons); a method for measuring the state of activity of this therapeutic target in subjects with established, incipient, or potential motoneuron disease; the discovery of drug agents that modulate neuronal microtubule dynamics in living subjects with motoneuron diseases; the discovery that administration of such agents, alone or in combinations, can provide marked neuroprotective therapy for living subjects with motoneuron diseases including delay in symptoms and prolongation of survival; and the discovery that monitoring of neuronal microtubule dynamics in subjects with motoneuron diseases, in response to therapeutic interventions, allows diagnostic monitoring for optimization of therapeutic regimen and strategy for individual subjects or for drug trials.
1. A method of treating a motoneuron disease in a patient wherein said motoneuron disease is selected from the group consisting of amyotrophic lateral sclerosis (ALS), diabetic neuropathy and Parkinson's disease comprising administering a pharmaceutical composition comprising a first microtubule target modulating agent (MTMA), wherein the first MTMA is noscapine.
2. A method according to claim 1 wherein the motoneuron disease is amyotrophic lateral sclerosis (ALS).
3. A method according to claim 1 , further comprising administering to said patient a first neuroprotective agent selected from the group consisting of a voltage gated ion channel antagonist, a peroxisome proliferation-activated receptor γ (PPARγ), an antioxidant, an L-VSCCs antagonist, an α-amino-3-hydroxy-5-methyl-4-isoxazolepropionic acid (AMPA) antagonist, nonselective blocker of glutamate receptor, an anandamine (AEA) reuptake inhibitor, and a second MTMA.
4. A method according to claim 3 , wherein when said first neuroprotective agent is a voltage gated ion channel antagonist, said first neuroprotective agent is a voltage gated calcium channel (VGCH) antagonist.
5. A method according to claim 4 , wherein said VGCH antagonist is N-methyl-D-aspartate (NMDA) receptor antagonist.
6. A method according to claim 5 , wherein said NMDA receptor antagonist is dizolcipine.
7. A method of treating a motoneuron disease in a patient wherein said motoneuron disease is selected from the group consisting of amyotrophic lateral sclerosis (ALS), diabetic neuropathy and Parkinson's disease comprising administering a pharmaceutical composition comprising a first microtubule target modulating agent (MTMA), wherein the first MTMA is a noscapine and N-methyl-D-aspartate (NMDA) receptor antagonist wherein said NMDA receptor antagonist is dizolcipine.
8. The method according to claim 7 , wherein the motoneuron disease is ALS.